MetaCap

AgomAb Therapeutics NV (AGMB) vs TRex Bio (TRXB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TRex Bio is the larger company by market cap ($297.0 million vs $268.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGMB-39.98%TRXB-26.32%
+13%-15%-43%
Oct 9, 20261 yearNov 20, 2026
AGMB-39.98%TRXB-26.32%
+2%-20%-42%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGMB versus TRXB key metrics
MetricAGMBTRXB
Share price$5.45$10.32
Market cap$268.40M$296.95M
1-day change-3.02%+6.12%
EPS (TTM)$-2.08$-2.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$17.82$16.56
52-week low$5.39$9.06
Distance from 52-week high-69.42%-37.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+591.19%+183.57%
Average volume208.99K156.80K
Shares outstanding49.25M28.79M
Employees6260
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AgomAb Therapeutics NV

AGMB stock →

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees

About TRex Bio

TRXB stock →

TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

AGMB vs TRXB FAQ

Which is bigger, AgomAb Therapeutics NV or TRex Bio?

TRex Bio (TRXB) is larger, with a market capitalization of $296.95M compared with $268.40M for AgomAb Therapeutics NV (AGMB).

Are AgomAb Therapeutics NV and TRex Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons